XSHG
603669
Market cap706mUSD
Oct 09, Last price
6.96CNY
1D
4.82%
1Q
12.62%
Jan 2017
-36.42%
IPO
3.01%
Name
Lionco Pharmaceutical Group Co Ltd
Chart & performance
P/E
—
P/S
15.39
EPS
—
Div yield, %
—
Shrs. gr., 5y
-1.59%
Rev. gr., 5y
-20.29%
Revenues
322m
-15.18%
Net income
-193m
L+47.78%
CFO
-132m
L+18.82%
Dividend
Jul 05, 20220.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lionco Pharmaceutical Group Co., Ltd., in collaboration with its various subsidiaries, actively participates in the entire lifecycle of pharmaceutical products within China, from initial research and development to manufacturing and sales. The company boasts a comprehensive portfolio of therapeutic solutions, encompassing medications for nutritional support, antimicrobial and antiviral treatments, digestive disorders, cardiovascular health, detoxification, and anti-tumor therapies, alongside other specialized products. Furthermore, it maintains dedicated research institutes that focus specifically on the advancement of chemical, natural, and biological drugs. Established in 2003, Lionco Pharmaceutical Group Co., Ltd. is headquartered in Shannan, China.
Key people
Hui Zhang
Vice Chairman of the Board · since 2022
Junke Zhang
Chief Financial Officer · since 2023
Lingping Tao
Chairman of the Board, General Manager · since 2012
Jun Lu
Deputy General Manager · since 2025
Guoping Sui
Deputy General Manager, Secretary of the Board · since 2024
Liming Liu
Deputy General Manager, Director · since 2024
Xiaogang Tao
General Manager · since 2025
Juling Du
Independent Director · since 2025
Qian He
Independent Director · since 2022
Hongxin Wang
Independent Director · since 2025
Ming Zhu
Independent Director · since 2025
Headquarters & legal address
山南市泽当镇乃东路68号乃东县商住楼第二幢一层
山南地区, XZ 850000
CN
山南地区, XZ 850000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||